Israeli-founded AI biotech Immunai expands AstraZeneca cancer collaboration
The expanded agreement extends and broadens the companies’ multi-year collaboration in oncology through 2027, according to the statement.| Read More JPost.com – Business & Innovation | The Jerusalem Post



